Infección por micobacterias no tuberculosas en inmunocompetentes

Martín, F. de Juan; Bravo, M.aC. Marín; Moreno, M.; Carrera, M.aA. Lezcano; Ara, L. Zubiri; Leza, M.aI. Adiego

doi:10.1016/s1695-4033(02)77817-x

Cited by 8 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ours is the 6th reported case of M. kansasii extrapulmonary lymphadenitis in immunocompetent adults; 5 cases in children under 18 have also been reported. (Table 1) [6], [7], [8], [9], [10], [11], [12], [13], [14]. Sites of dissemination included cervical and mediastinal lymph nodes, skin, brain, soft tissue, joint, and peritoneum.…”

Section: Discussionmentioning

confidence: 99%

Ethambutol-resistant Mycobacterium kansasii cervical lymphadenitis in an immunocompetent adult patient: A case report and literature review

Asensi

Palacios

Rivas-Carmenado

et al. 2020

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

Mycobacterium kansasii extrapulmonary infections are infrequent in immunocompetent adults. Rifampin (RIF), clarithromycin (CLR), isoniazid (INH) and ethambutol (EMB) are included in all the standard regimens against M.kansasii. We report a case of a healthy 65-year-old male farmer who presented with isolated right supraclavicular lymphadenopathy. The lymph node FNA showed acid-fast-bacilli and granulomatous inflammation. Quantiferon TB Gold test, HIV serology, and functional immunological studies were all negative or normal. He was put on a standard 4 drugs anti-tuberculous regimen that was switched to RIF + CLR+ INH after the Microbiology lab demonstrated an EMB–resistant Mycobacterium kansasii isotype I strain. The patient was cured after 12 months of therapy. This is the 6th reported case of M. kansasii extrapulmonary lymphadenitis in an immunocompetent adult and the 2nd showing EMB resistance in the world literature. Antimycobacterial regimens against M. kansasii, classically resistant to pyrazinamide (PZA) might also exclude EMB due to its increasing resistance in Europe. A 612 months therapy with at least 2 effective antimycobacterial drugs including RIF + CLR might be enough to treat extrapulmonary M. kansasii infections in immunocompetents.

show abstract

Section: Discussionmentioning

confidence: 99%

Ethambutol-resistant Mycobacterium kansasii cervical lymphadenitis in an immunocompetent adult patient: A case report and literature review

Asensi

Palacios

Rivas-Carmenado

et al. 2020

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

show abstract

“…La evolución natural de la LAMNT varía desde involución espontánea (que produce fibrosis y calcificación) hasta cronicidad con fistulizaciones recurrentes y cicatriz hipertrófica tipo queloide (lo más habitual). 5 Las MNT están presentes en el agua, la tierra, la leche, los animales (principalmente, las aves) y el instrumental sanitario. Tras la inhalación, inoculación o ingestión de material contaminado, se produce la infección de los ganglios cervicales en el 90% de los casos.…”

Section: Discussionunclassified

Linfadenitis por Mycobacterium lentiflavum. Reporte de dos casos

et al. 2016

View full text Add to dashboard Cite

Presentación de casos clínicos RESUMENLa linfadenitis es la manifestación clínica más frecuente de la infección por micobacterias no tuberculosas en niños inmunocompetentes. Se presentan dos casos de linfadenitis por M. lentiflavum diagnosticados en un hospital de tercer nivel en los últimos 10 años. Se realizaron pruebas complementarias de rutina ante adenopatía persistente y se obtuvo una muestra mediante drenaje para el cultivo, que resultó positivo para este germen. Ambos pacientes recibieron tratamiento antibiótico oral durante varias semanas. El caso 1 precisó exéresis completa al quinto mes de evolución, mientras que el caso 2 presentó resolución completa de la lesión a los 4 meses. M. lentiflavum es considerado, de entre las nuevas especies de micobacterias no tuberculosas recientemente descritas, un germen emergente en nuestro medio. Posee unas características microbiológicas y clínicas especiales, diferentes del resto de las micobacterias no tuberculosas. Son pocos los casos publicados hasta la fecha desde que se describió por primera vez la infección en 1997. Palabras clave: linfadenitis, micobacterias no tuberculosas, Mycobacterium lentiflavum, macrólidos. ABSTRACTLymphadenitis is the most common clinical feature in nontuberculous mycobacterium infection in immunocompetent children. We present two case reports of M. lentiflavum lymphadenitis diagnosed in a tertiary hospital in the last 10 years. Routine tests were performed after persistent adenopathy, and a sample for culture was obtained, being positive for this microorganism. Both patients received oral antibiotics during several weeks. Case 1 needed complete excision after five months

show abstract